

## Effect of Artesunate on Haematological and Plasma Biochemical Parameters in Female Wistar Rats

K.O. Oyedeji\* and A. Abiodun

Department of Physiology, College of Medicine and Health Sciences,  
Afe Babalola University, Ado-Ekiti, Nigeria.

\*Corresponding Author Email: sinaoyedeji@yahoo.com

<https://dx.doi.org/10.13005/bpj/2706>

(Received: 25 December 2022; accepted: 14 March 2023)

This study was designed to investigate effect of artesunate on blood parameters in female rats. Ten female Wistar rats (130 – 150 g) were grouped into control and artesunate (1.43 mg/kg) – treated groups for blood assay. The artesunate was administered orally for 50 days. Hematological assay was carried out using hemocytometer, while biochemical assay was carried out using spectrophotometry. Mean  $\pm$  SEM and student's t-test at  $p < 0.05$  were determined. Artesunate (1.43 mg/kg) significantly reduced RBC, platelet and lymphocyte counts when compared to their controls. It also significantly decreased total protein, ALT and ALP values relative to their controls. However, it induced no significant changes in the PCV, Hb, TWBC, neutrophil, monocyte, eosinophil, MCV, MCHC, MCH, albumin, globulin, AST, BUN and creatinine values relative to their controls. Conclusively, it can be suggested that artesunate had both harmful and advantageous effects on blood parameters in female rats.

**Keywords:** Artesunate, Red blood cell, Lymphocyte, Total protein, Rats.

Artesunate is a drug used to cure malaria<sup>1</sup>. It belongs to the artemisinin class of drugs. It is frequently administered in the form of combination therapy, for example artesunate combine with mefloquine. It is not used as a prophylaxis. Artesunate can be administered through intravenous injection, muscular injection as well as through oral and rectal administrations<sup>2</sup>.

The drug is well tolerated when taken<sup>3</sup>. It is preferred during the gestation period because of its high safety index, however contrary results were suggested by animal studies<sup>4</sup>. It is also allowed to be taken by lactating mothers. Liu Xu invented this

drug in 1977<sup>5</sup> and the World Health Organization has listed it as an essential medicine<sup>6</sup>. Although artesunate is used mainly to treat malaria, evidence abounds that it could also has advantageous effects on infection due *Schistosoma haematobium*<sup>7</sup>, but this has not been proven convincingly.

Its efficacy is similar to that of arthemeter when used to treat adults' malaria induced by *P. falciparum*<sup>8</sup>, however artesunate in combination with other drugs has superior advantages relative to artemether-based drugs, vis-à-vis, through uptake and through the routes of administration and probably could be more efficacious when treating serious malaria in children<sup>9</sup>. Drugs that inactivate

hepatic enzyme CYP2A6 should not be taking alongside with artesunate, examples of such drugs are amiodarone, letrozole isoniazid e.t.c.

The effect of artesunate on: rats' kidneys toxicity<sup>10</sup>, hemolysis and hypoglycemia induction in rats<sup>11</sup>, developmental toxicities in rats and rabbits<sup>12</sup>, hepatic histopathological changes in rats<sup>13</sup>, embryotoxicity and toxicokinetics in rats<sup>14</sup>, bone development toxicity in rats<sup>15</sup>, reproductive function in female rats<sup>16</sup>, stroke and other central nervous system therapeutic effects<sup>17</sup> as well as on sub-chronic hemato-biochemical effects in rats<sup>18</sup> have been reported.

But, as a result of limited information obtained concerning the activities of artesunate on blood parameters in female rats, hence, this research intends to bridge this gap.

## MATERIALS AND METHODS

### Experimental Animals

Ten female rodents of weight range 130 – 150 g raised in the Animal Holding of ABUAD were used in the current study. These rodents were accommodated in a conducive laboratory atmosphere with unlimited supply of feed and water; the acclimatization period was for two weeks. All animal experiments were carried out in accordance with ABUAD Ethical Committee (16/ MHS01/015) on care and use of laboratory animals.

### Drug

Artesunate (Green Energy, China) was purchased from Danax Pharmacy, Ibadan, Nigeria. Among these, artesunate (50 mg) was liquefied in 10 ml of distilled water to produce a concentration of 5.0 mg/ml. The dosage of the artesunate considered in this research was as recommended by the manufacturer.

Dosage: According to the manufacturer, for adult 2 tablets (each tablet weighed 50 mg) were to be given orally per day for a 70 kg adult.

Hence, 50 mg (x2) per day in a 70 kg adult.

Therefore, dose to be used =  $100/70$  mg/kg  
= 1.43 mg/kg

### Experimental Design

Ten matured female rats (five per group) used for this study received the following oral doses of artesunate and distilled water (control) for 50 days as follows:

Group A rodents (control group) were given 0.5 ml/100 g of distilled water.

Group B rodents were given 1.43 mg/kg of artesunate.

### Blood sample collection

On day 51, blood samples were collected from the rodents and prepared as previously described<sup>19</sup>.

### Haematological Parameters Determination

The red blood cells (RBC) count, white blood cells (WBC) count, hemoglobin (Hb) concentration, packed cell volume (PCV), mean

**Table 1.** Effect of treating rats with artesunate for 50 days on haematological parameters

Parameters	Control	Artesunate (1.43 mg/kg)
PCV (%)	51.50 ± 0.66	49.00 ± 0.15
Hb (g/dL)	16.75 ± 0.34	15.90 ± 0.61
RBC ( $\times 10^6/\mu\text{L}$ )	8.66 ± 0.04	7.98 ± 0.11*
TWBC ( $\times 10^3/\mu\text{L}$ )	10.76 ± 0.36	4.24 ± 0.83
Platelet ( $\times 10^5/\mu\text{L}$ )	1.34 ± 0.08	0.68 ± 0.07*
Lymphocyte (%)	74.25 ± 0.85	71.75 ± 0.83*
Neutrophil (%)	23.50 ± 0.89	25.25 ± 0.75
Monocyte (%)	1.75 ± 0.31	1.50 ± 0.28
Eosinophil (%)	0.50 ± 0.14	1.50 ± 0.36
MCV (fL)	59.46 ± 0.15	61.33 ± 0.12
MCHC (g/dL)	32.53 ± 0.24	32.47 ± 0.21
MCH (pg)	19.34 ± 0.14	19.91 ± 0.20

(n=5, \*p<0.05)

corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC) were determined as previously reported <sup>19</sup>.

#### Biochemical Parameters Determination

The total protein concentration, albumin concentration, globulin concentration, activities of plasma alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP), levels of creatinine and urea (BUN) were determined as previously reported <sup>20</sup>.

#### Statistical analysis

Mean +/- SEM and student's t-test at  $p < 0.05$  were determined.

### RESULTS

From table 1, treatment of rodents with artesunate (1.43 mg/kg) induced significant ( $p < 0.05$ ) reductions in RBC, platelet and lymphocyte values relative to their controls. However, the table also revealed that treatment of rodents with artesunate (1.43 mg/kg) caused non-significant ( $p > 0.05$ ) changes in the other parameters as shown in the table.

From table 2, it was revealed that treatment of rodents with artesunate (1.43 mg/kg) caused significant ( $p < 0.05$ ) reductions in total protein, ALT and ALP values when compared to their controls. However, the table also revealed that treatment of rodents with artesunate (1.43 mg/kg) produced non-significant ( $p > 0.05$ ) changes in the other parameters as shown in the table.

### DISCUSSION

The results have revealed that artesunate induced significant reduction in RBC value which suggests that the drug prevented erythropoietin secretion by the kidneys and caused decrease in oxygen binding capacity of blood with ultimate reduction in the quantity of oxygen transported to the tissues. Similar account was given by <sup>21</sup> in rodents treated with extract of *Plectranthus amboinicus*. This result was corroborated by the assertions of <sup>22,23</sup>.

Also, artesunate induced significant decrease in the platelet count which suggests that it prevented the haemostatic function of the body. Opposite result was given by <sup>24</sup> in rats treated with extract of *Fadogia agrestis*.

The drug caused insignificant change in TWBC value which suggests that it had no effect on resistance of the body to foreign pathogens. Opposite result was given by <sup>25</sup> in rodents treated with extract of *Viscum album*. This result was supported by the assertions of <sup>26</sup>.

Artesunate produced significant decrease in lymphocyte count which could signify the body acquired immune suppression. Opposite result was given by <sup>27</sup> in rodents treated with isolated ergosterol.

Further, the drug produced non-significant change in eosinophil value which suggests the absence of anti-allergic and anti-parasitic infectious responses by the drug. Opposite result was given by <sup>28</sup> in rats and mice treated with extract of *Arctotis actotooides*.

**Table 2.** Effect of treating rats with artesunate for 50 days on plasma biochemical parameters

Parameters	Control	Artesunate (1.43 mg/kg)
Total Protein (g %)	8.70 ± 0.07	8.33 ± 0.12*
Albumin (gm %)	3.40 ± 0.08	3.40 ± 0.14
Globulin (gm %)	5.30 ± 0.04	4.93 ± 0.12
AST (µ/L)	45.00 ± 0.92	42.25 ± 1.03
ALT (µ/L)	33.25 ± 0.63	31.50 ± 0.74*
ALP (IU/L)	113.00 ± 1.93	110.50 ± 2.23*
BUN (mg/dL)	17.53 ± 0.17	17.30 ± 0.13
Creatinine (µmol/L)	0.78 ± 0.02	0.73 ± 0.03

(n=5, \* $p < 0.05$ )

Artesunate caused non-significant change in the neutrophil value which suggests the drug had no effect on the body response to pathogenic bacteria, viruses and other harmful agents. Opposite result was given by <sup>29</sup> in rodents treated with extract of *Dennettia tripetala*.

The drug induced non-significant change in the monocyte value which suggests that it lacked phagocytic function <sup>30</sup>. Opposite result was given by <sup>31</sup> in hens fed with *Saccharomyces cerevisiae*.

Artesunate produced non-significant changes in MCV and MCH values which suggests the absence of effect on macrocytic anaemia induction. Similar account was given by <sup>32</sup> in rats treated with extract of *Jatropha gossypifolia*.

The drug produced insignificant change in the MCHC value which suggests absence of effect on hereditary spherocytosis induction. Similar account was given by <sup>32</sup> in rats treated with extract of *Jatropha gossypifolia*.

It has been reported that treatment of rats for 45 days with artesunate (2 mg/kg and 4 mg/kg) caused non-significant changes in hemoglobin, RBC, MCH, MCHC, lymphocytes and platelet values; but, the study also revealed that at 8.0 mg/kg, it caused significant ( $p < 0.01$ ) increase in PCV, MCH, TWBC, neutrophil and eosinophil values <sup>18</sup>.

The plasma biochemical study results have revealed that artesunate caused significant reduction in total protein level which suggests that the drug inhibited blood buffering capacity and also decrease the colloidal osmotic pressure. Opposite result was given by <sup>33</sup> in rodents treated with extract of *Euphorbia heterophylla*. This result was validated by the assertion of <sup>26</sup>

In addition, artesunate produced significant reduction in ALT activity which could mean that it prevented the induction liver damage. Opposite result was given by <sup>34</sup> in rodents treated with extract of *Moringa oleifera*.

Artesunate caused significant decrease in ALP activity which suggests the inhibition of cholestasis. Opposite result was given by <sup>35</sup> in rats treated with losartan. This result was corroborated by the assertion of <sup>36</sup>.

Artesunate induced non-significant change in the level of albumin which suggests that it had no effect on the levels of essential plasma components like amino acids, metals, bilirubin e.t.c. Contrary result was given by <sup>37</sup> in rats treated

with extract of *Enicostemma axillare*.

Artesunate caused non-significant change in globulin level which suggests the lack of effect on both the natural and acquired immunity of the body. Similar account was given by <sup>38</sup> in rats treated with extracts of *Portulaca oleracea*.

The drug caused insignificant change in AST activity which could mean the lack of effect on induction of tissue necrosis. Opposite result was given by <sup>39</sup> in rodents treated with extract of *Sida rhombifolia*.

Artesunate caused non-significant change in BUN level which suggests the absence of nephrotoxicism. Opposite result was given by <sup>40</sup> in rats treated with extract of *Passiflora edulis*. This result was corroborated by the assertion of <sup>41</sup>.

Artesunate produced non-significant change in creatinine level which suggests the absence of renal dysfunction. Opposite result was given by <sup>42</sup> *Mucuna pruriens* extract treated rats.

It has also been reported that treatment of rats for 45 days with artesunate (4 mg/kg and 8 mg/kg) caused significant ( $p < 0.05-0.001$ ) increase in SGOT, SGPT, ALP, TC, TG values; at 8.0 mg/kg, it also caused significant ( $p < 0.05$ ) increase in bilirubin level. However, at 2.0 mg/kg, 4.0 mg/kg and 8.0 mg/kg, it caused non-significant changes in total protein, albumin, creatinine and urea levels <sup>18</sup>.

## CONCLUSION

Conclusively, it can be suggested that artesunate had both harmful and advantageous effects on blood parameters in female Wistar rats.

## ACKNOWLEDGEMENTS

The authors would like to acknowledge the Management of Afe Babalola University, Ado-Ekiti for supporting this work.

### Limitations of the study

Scantiness of prior research studies on the topic: There were limited information obtained from literature concerning the activities of artesunate on blood parameters in female rats prior to the commencement of this study.

### Competing interest

There is absence of conflicting interests in this study.

## REFERENCES

1. World Health Organization. Artesunate. March 2013. Archived from the original (PDF) on 28 December 2013. Retrieved 7 December 2016.
2. World Health Organization. *Rectal artesunate for pre-referral treatment of severe malaria. Global Malaria Programme (Report)*. World Health Organization, 2018.
3. Rosenthal P.J. Artesunate for the treatment of severe falciparum malaria. *The New England J. Med.*, 2008; 358 (17): 1829–1836.
4. Kovacs S.D, Rijken M.J and Stergachis A. Treating severe malaria in pregnancy: a review of the evidence. *Drug Safet.*, 2015; 38 (2): 165–181.
5. Li G., Li Y., Li Z. and Zeng M. Artemisinin-based and other antimalarials: detailed account of studies by Chinese scientists who discovered and developed them. Academic Press, 2017; ISBN 9780128132111.
6. World Health Organization. *World Health Organization model list of essential medicines: 21st list 2019*. Geneva: World Health Organization, 2019.
7. Boulanger D., Dieng Y., Cisse B., Remoue F., Capuano F., Dieme J.L, *et al.* Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. *Transact. Royal Societ. Tropic. Med. Hyg.*, 2007; 101 (2): 113–116.
8. Phu N.H, Tuan P.Q, Day N., Mai N.T, Chau T.T, Chuong L.V, *et al.* Randomized controlled trial of artesunate or artemether in Vietnamese adults with severe falciparum malaria. *Malaria J.*, 2010; 9 (1): 97.
9. Li Q. and Weina P. Artesunate: The best drug in the treatment of severe and complicated malaria. *Pharmaceuticals.*, 2010; 3 (7): 2322–2332.
10. Danladi S.A, Mumuni M., Joseph V.Z, Aminu A.R, Nuhu S., Lucy A. and Tarfa M. Effect of oral administration of artesunate on the histology of the kidney in albino rat. *IOSR J. Dent. Med. Sci.*, 2013; 3 (5): 15-20.
11. Salman M.T, Peter O., Abdullateef I.A and Lawrence A.O. Artesunate-induced hemolysis and hypoglycemia in rats: Gender implication and role of antioxidant enzymes. *J. Appl. Hem.*, 2017; 8 (1): 23-32.
12. Clark R.L, Tacey E.K.W, Sally A.C, Ian G., Peter W. and Stephen A.W. Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. *Birth Defects Res. B. Dev. Reprod. Toxicol.*, 2004; 71 (6): 380-394.
13. Mohamed S.A, Muheet A.S, Mukhtar A. and Sarah M. Histopathological changes induced by artesunate in liver of Wistar rat. *Inter. J. Pharmacol.*, 2017; 13: 104-108.
14. Moon-Koo C., Wook-Joon Y., Jin-Soo L. and Jong-Hwa L. Embryotoxicity and toxicokinetics of the antimalarial artesunate in rats. *Toxicol. Res.*, 2013; 29 (1): 27 - 34.
15. Adebisi S. Assessment of the effect of artesunate on the developing bones of wistar rat animal model of malaria treatment. *AF Prev. Med. Bull.*, 2010; 9 (1): 23 - 28.
16. Oyedeji K.O. Effect of artesunate on reproductive function in female Wistar rats. *Int. J. Pharm. Sci. Rev. Res.*, 2021; 71 (2): 72-75.
17. Shilun Z., Qiang L., Xin L., Hua F. and Yujie C. The potential therapeutic effect of artesunate on stroke and other central nervous system diseases. *Biomed. Res. Inter.*, 2016; |Article ID 1489050.
18. Bigoniya P., Sahu T. and Tiwari V. Hematological and biochemical effects of sub-chronic artesunate exposure in rats. *Toxicol Rep.*, 2015; 2: 280-288.
19. Oyedeji K.O., Adurodija M.N., Adeleye A.S. and Abidoye D. Effect of ethanol extract of *Adenopus breviflorus* on haematological and plasma biochemical parameters in male albino rats. *Int. J. Pharm.Sci.Rev. Res.*, 2015; 35: 36-40.
20. Oyedeji K.O., Okeke O.E., Adeleke K.O. and Oni J. Effect of atenolol (Beta blocker) on haematological and plasma biochemical parameters in male Wistar rats. *Int. J. Pharm. Sci. Rev. Res.*, 2019; 54 (2): 1-5.
21. Melva S. and Pasar M.S. Haematological profile of rats (*Rattus norvegicus*) induced BCG and provided leaf extract of *Plectranthus amboinicus*. The 4th Inter. Conf. on Res., Implement., and Edu. Maths. Sci.; 2017.
22. Polenakovic M. and Sikole A. Is erythropoietin a survival factor for red blood cells? *J. Am. Soc. Nephrol.*, 1996; 7 (8): 1178 - 1182.
23. American Diabetes Association. Nutrition recommendation and principles for people with diabetes mellitus clinical practice recommendations. *Diabet Care.*, 2000; 23:543-546.
24. Yakubu M.T, Akanji M.A and Oladiji A.T. Hematological evaluation in male albino rats following chronic administration of aqueous extract of *Fadogia agrestis* stem. *Pharmacog. Mag.*, 2007; 3: 34 - 38.
25. Imoru J.O, Eno A.E, Unoh F.B, Enkanu E., Ofem O.E and Ibu J.O. Haematopoietic agents in the crude extracts from the leaves of *Viscum album* (mistletoe). *Nigerian J. Health Biomed. Sci.*, 2005; 4 (2): 139-145.
26. Ganong W.F. Review of Medical Physiology

- (22<sup>nd</sup>). New York, Lange Medical books/Mc Graw Hill; 2005.
27. Oyedeji K.O, Bolarinwa A.F and Oladosu I.A. Effect of isolated ergosterol constituent of *Portulaca oleracea* on Haematological Parameters in male albino rats. *Asian J. Pharm. Clinic Res.*, 2013; 6: 2.
28. Jimoh F.O, Adedapo A.A, Sofidiya M.O, Masika P.J and Afolayan A.J. Safety evaluation of the extract from the shoots of *Arctotis actotoides* in rats and mice. *Afri. J. Biotech.*, 2008; 7 (18): 3173-3177.
29. Ikpi D.E and Nku C.O. Effect of ethanolic extract of *Dennettia tripetala* fruit on haematological parameters in albino Wistar rats. *Nigerian J. Physiol. Sci.*, 2008; 23(1-2): 13-17.
30. Guyton A.C and Hall J.E. Textbook of Medical Physiology, 11th edition, Elsevier Inc; 2006.
31. Matur E., Erqul E., Erasian E., Inal G., Bilgic S. and Demircan H. Effect of *Saccharomyces cerevisiae* extract on haematological parameters, immune functions and the antioxidant defense system in breeder hens fed aflatoxin contaminated diets. *British Poultr. Sci.*, 2011; 52 (5): 541-550.
32. Oyedeji K.O, Awoyinka D. and Abidoye D. Effect of ethanol extract of *Jatropha gossypifolia* on haematological and plasma biochemical parameters in male albino rats. *Int. J. Pharm. Sci. Rev. Res.*, 2015; 35 (2): 41-45.
33. Apiamu A. and Evuen U.F. Biochemical assessment of the effect of aqueous leaf extract of *Euphorbia Heterophylla Linn* in hepatocytes of rats. *IOSR J. Environ. Sci, Toxicol. Food Tech.*, 2013; 3 (5): 37- 41.
34. Ajibade T.O, Olayemi F.O and Arowolo R.O.A. The haematological and biochemical effects of methanol extract of the seeds of *Moringa oleifera* in rats. *J. Med. Plant Res.*, 2012; 6 (4): 615-621.
35. Oyedeji K.O, Okeke O.E, Talabi Y.J and Oyawale G. Effect of losartan (Angiotensin II antagonist) on haematological and biochemical parameters in male Wistar rats. *J. Pharm. Sci. Res.*, 2018; 10 (5): 995-998.
36. Vasudevan D.M and Sreekumari S. Textbook for biochemistry for medical students. Jaypee Brothers Medical Publishers Ltd, New Delhi, 5<sup>th</sup> ed, 266; 2007.
37. Gite V.N, Pokharkar R.D, Chopade V.V and Takate S.B. Hepato-Protective activity of *Enicostemma Axillare* in paracetamol induced hepato-toxicity in albino rats. *Inter. J. Pharm. Life Sci.*, 2010; 1 (2): 50 – 53.
38. Oyedeji K.O and Bolarinwa A.F. Effects of crude Extracts of *Portulaca oleracea* on haematological parameters in albino rats. *Afri. J. Biomed. Res.*, 2010; 15: 41- 47.
39. Ouedraogo M., Zerbo P., Konate K., Barro N., Laya L. and Sawadogo. Effect of long-term use of *Sida rhombifolia L.* extract on haematological parameters of experimental animals. *British J. Pharmacol. Toxicol.*, 2013; 4 (1): 18-24.
40. Devaki K., Beulah U., Akila G. and Gopalakrishnan V.K. Effect of aqueous extract of *Passiflora edulis* on biochemical and haematological parameters of wistar albino rats. *Toxicol. Inter.*, 2012; 19 (1): 63-67.
41. Oduola T., Adeosun G.O, Oduola T.A, Avwioro G.O. and Oyeniyi M.A. Mechanism of action of *Jatropha gossypifolia* stem latex as a haemostatic agent. *Euro. J. Gen. Med.*, 2005; 2 (4): 140–143.
42. Adepoju O.O and Odubena J.A. Effect of *Mucuna pruriens* on some hematological and biochemical parameters. *J. Med. Plants Res.*, 2009; (3): 73-76.